Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650923 · ClinicalTrials.gov registry record · Phase 1
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT00650923: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00650923 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00650923, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of aflibercept when given together with radiation therapy and temozolomide in treating patients with newly diagnosed or recurrent glioblastoma multiforme, gliosarcoma, or other malignant glioma. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving aflibercept together with radiation therapy and temozolomide may kill more tumor cells.
Interventions
- DRUG temozolomide
- PROCEDURE laboratory biomarker analysis
- PROCEDURE radiation therapy
- DRUG ziv-aflibercept
- PROCEDURE pharmacological study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650923
The ClinicalTrials.gov registry entry for NCT00650923 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which temozolomide is the first listed.
NCT00650923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650923 about?
NCT00650923 is a clinical study titled "Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma". This phase I trial is studying the side effects and best dose of aflibercept when given together with radiation therapy and temozolomide in treating patients with newly diagnosed or recurrent glioblastoma multiforme, gliosarcoma, or other malignant glioma. Aflibercept may stop the growth of tumor ce...
What is the current status of trial NCT00650923?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2008-07. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00650923?
The interventions under investigation include: temozolomide (DRUG), laboratory biomarker analysis (PROCEDURE), radiation therapy (PROCEDURE), ziv-aflibercept (DRUG), pharmacological study (PROCEDURE).
Who is sponsoring clinical trial NCT00650923?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.